Sorafenib Long Term Extension Program
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms STEP
- Sponsors Bayer
- 10 Sep 2018 Planned End Date changed from 28 Jun 2019 to 30 Jun 2020.
- 10 Sep 2018 Planned primary completion date changed from 28 Jun 2019 to 30 Jun 2020.
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.